140 related articles for article (PubMed ID: 35676195)
1. Recommendations for oral treatment for adult patients with type 1 Gaucher disease.
Torralba-Cabeza MÁ; Morado-Arias M; Pijierro-Amador A; Fernández-Canal MC; Villarrubia-Espinosa J
Rev Clin Esp (Barc); 2022 Jun; ():. PubMed ID: 35676195
[TBL] [Abstract][Full Text] [Related]
2. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
[TBL] [Abstract][Full Text] [Related]
3. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
Belmatoug N; Di Rocco M; Fraga C; Giraldo P; Hughes D; Lukina E; Maison-Blanche P; Merkel M; Niederau C; Plӧckinger U; Richter J; Stulnig TM; Vom Dahl S; Cox TM
Eur J Intern Med; 2017 Jan; 37():25-32. PubMed ID: 27522145
[TBL] [Abstract][Full Text] [Related]
4. Metabolizing profile of the cytochrome pathway CYP2D6, CYP3A4 and the ABCB 1 transporter in Spanish patients affected by Gaucher disease.
Almeida-Calpe A; López de Frutos L; Medrano-Engay B; García-García CB; Ribate MP; Giraldo P
Chem Biol Interact; 2021 Aug; 345():109527. PubMed ID: 34058179
[TBL] [Abstract][Full Text] [Related]
5. Eliglustat: A Review in Gaucher Disease Type 1.
Scott LJ
Drugs; 2015 Sep; 75(14):1669-78. PubMed ID: 26384672
[TBL] [Abstract][Full Text] [Related]
6. Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study.
Camou F; Lagadec A; Coutinho A; Berger MG; Cador-Rousseau B; Gaches F; Belmatoug N
Mol Genet Metab; 2023 Nov; 140(3):107667. PubMed ID: 37597334
[TBL] [Abstract][Full Text] [Related]
7. Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States.
Nalysnyk L; Sugarman R; Cele C; Uyei J; Ward A
J Manag Care Spec Pharm; 2018 Oct; 24(10):1002-1008. PubMed ID: 30247105
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials.
Lukina E; Balwani M; Belmatoug N; Watman N; Hughes D; Gaemers SJM; Foster MC; Lewis G; Peterschmitt MJ
JIMD Rep; 2021 Jan; 57(1):76-84. PubMed ID: 33473343
[TBL] [Abstract][Full Text] [Related]
9. Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy.
Istaiti M; Becker-Cohen M; Dinur T; Revel-Vilk S; Zimran A
J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362492
[TBL] [Abstract][Full Text] [Related]
10. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
Bennett LL; Turcotte K
Drug Des Devel Ther; 2015; 9():4639-47. PubMed ID: 26345314
[TBL] [Abstract][Full Text] [Related]
11. Goal-oriented therapy with miglustat in Gaucher disease.
Pastores GM; Giraldo P; Chérin P; Mehta A
Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
[TBL] [Abstract][Full Text] [Related]
12. A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat.
Abrams R; Kaddi CD; Tao M; Leiser RJ; Simoni G; Reali F; Tolsma J; Jasper P; van Rijn Z; Li J; Niesner B; Barrett JS; Marchetti L; Peterschmitt MJ; Azer K; Neves-Zaph S
CPT Pharmacometrics Syst Pharmacol; 2020 Jul; 9(7):374-383. PubMed ID: 32558397
[TBL] [Abstract][Full Text] [Related]
13. Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1.
Vu L; Cox GF; Ibrahim J; Peterschmitt MJ; Ross L; Thibault N; Turpault S
Mol Genet Metab Rep; 2020 Mar; 22():100552. PubMed ID: 31993325
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States.
Balwani M; Burrow TA; Charrow J; Goker-Alpan O; Kaplan P; Kishnani PS; Mistry P; Ruskin J; Weinreb N
Mol Genet Metab; 2016 Feb; 117(2):95-103. PubMed ID: 26387627
[TBL] [Abstract][Full Text] [Related]
15. Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease.
Kleytman N; Ruan J; Ruan A; Zhang B; Murugesan V; Lin H; Guo L; Klinger K; Mistry PK
Mol Genet Metab Rep; 2021 Dec; 29():100798. PubMed ID: 34485083
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
Mistry PK; Balwani M; Charrow J; Kishnani P; Niederau C; Underhill LH; McClain MR
Am J Hematol; 2020 Sep; 95(9):1038-1046. PubMed ID: 32438452
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
Cox TM; Charrow J; Lukina E; Mistry PK; Foster MC; Peterschmitt MJ
Genet Med; 2023 Feb; 25(2):100329. PubMed ID: 36469032
[TBL] [Abstract][Full Text] [Related]
18. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
Lukina E; Watman N; Dragosky M; Lau H; Avila Arreguin E; Rosenbaum H; Zimran A; Foster MC; Gaemers SJM; Peterschmitt MJ
Am J Hematol; 2019 Jan; 94(1):29-38. PubMed ID: 30264864
[TBL] [Abstract][Full Text] [Related]
19. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.
Sidhu K; Boyd SK; Khan A
Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
